Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms.

Author(s): Honda K,  Kobayashi M,  Okusaka T,  Rinaudo JA,  Huang Y,  Marsh T,  Sanada M,  Sasajima Y,  Nakamori S,  Shimahara M,  Ueno T,  Tsuchida A,  Sata N,  Ioka T,  Yasunami Y,  Kosuge T,  Miura N,  Kamita M,  Sakamoto T,  Shoji H,  Jung G,  Srivastava S,  Yamada T

Journal: Sci Rep

Date: 2015 Nov 9

Major Program(s) or Research Group(s): CBRG

PubMed ID: 26549697

PMC ID: PMC4637825

Abstract: We recently reported that circulating apolipoprotein AII (apoAII) isoforms apoAII-ATQ/AT (C-terminal truncations of the apoAII homo-dimer) decline significantly in pancreatic cancer and thus might serve as plasma biomarkers for the early detection of this disease. We report here the development of novel enzyme-linked immunosorbent assays (ELISAs) for measurement of apoAII-ATQ/AT and their clinical applicability for early detection of pancreatic cancer. Plasma and serum concentrations of apoAII-ATQ/AT were measured in three independent cohorts, which comprised healthy control subjects and patients with pancreatic cancer and gastroenterologic diseases (n = 1156). These cohorts included 151 cases of stage I/II pancreatic cancer. ApoAII-ATQ/AT not only distinguished the early stages of pancreatic cancer from healthy controls but also identified patients at high risk for pancreatic malignancy. AUC values of apoAII-ATQ/AT to detect early stage pancreatic cancer were higher than those of CA19-9 in all independent cohorts. ApoAII-ATQ/AT is a potential biomarker for screening patients for the early stage of pancreatic cancer and identifying patients at risk for pancreatic malignancy (161 words).